#  @mike98572986 mike mike posts on X about $clpt, $qure, $4503t, health the most. They currently have [-----] followers and [--] posts still getting attention that total [-----] engagements in the last [--] hours. ### Engagements: [-----] [#](/creator/twitter::1422364980339380240/interactions)  - [--] Week [-----] -22% - [--] Month [------] -69% - [--] Months [-------] +396% - [--] Year [-------] +1,825% ### Mentions: [--] [#](/creator/twitter::1422364980339380240/posts_active)  - [--] Month [--] -70% - [--] Months [---] +265% - [--] Year [---] +2,219% ### Followers: [-----] [#](/creator/twitter::1422364980339380240/followers)  - [--] Week [-----] +0.31% - [--] Month [-----] +3.90% - [--] Months [-----] +145% - [--] Year [-----] +433% ### CreatorRank: [-------] [#](/creator/twitter::1422364980339380240/influencer_rank)  ### Social Influence **Social category influence** [social networks](/list/social-networks) 3.13% [technology brands](/list/technology-brands) 3.13% **Social topic influence** [$clpt](/topic/$clpt) #3, [$qure](/topic/$qure) #23, [$4503t](/topic/$4503t) #8, [health](/topic/health) 9.38%, [$rgnx](/topic/$rgnx) #17, [real world](/topic/real-world) #1358, [ai](/topic/ai) 6.25%, [in the](/topic/in-the) 6.25%, [$par](/topic/$par) #3, [we are](/topic/we-are) 6.25% **Top accounts mentioned or mentioned by** [@biggercapital](/creator/undefined) [@petermantas](/creator/undefined) [@desertdweller93](/creator/undefined) [@profdollar](/creator/undefined) [@fiercebiotech](/creator/undefined) [@thephiloinvest](/creator/undefined) [@reignots](/creator/undefined) [@lvgtoft](/creator/undefined) [@long_only_guy](/creator/undefined) [@spacechocolate7](/creator/undefined) **Top assets mentioned** [uniQure N.V. (QURE)](/topic/$qure) ### Top Social Posts Top posts by engagements in the last [--] hours "$clpt big time right here A Study of ASP2246 for People Who Have Movement Problems Caused by Brain Injury After a Stroke Astellas Pharma Inc Intracerebral parenchymal infusion via SmartFlow Neuro cannula. Procedure: Brain surgery Stereotactic brain surgery Study start 2026-02-09 [--] for enrollment @peter_mantas @biggercapital" [X Link](https://x.com/mike98572986/status/2009095523215524221) 2026-01-08T02:51Z [----] followers, [----] engagements "@biggercapital Yeah Astellas is no joke they likely saw clearpoints work on AviadoBio and were impressed with what they saw. This is definitely a big program and big partner to have" [X Link](https://x.com/mike98572986/status/2009106380318200173) 2026-01-08T03:34Z [----] followers, [----] engagements "$qure $clpt a good time to bring awareness to the disease Will Forte Gets Candid About His Family's Health Journey with Huntington's Disease" [X Link](https://x.com/mike98572986/status/2017705264770924668) 2026-01-31T21:03Z [----] followers, [----] engagements "I wouldnt go all in they are in a good position but a lot can go wrong. Just like a lot can also go right. My largest position but I believe so far the biggest risk is something coming out that is better and easier to deliver to the brain. There is definitely stuff out there working on this. I even actually expect it good news is that this industry moves extremely slow and by the time a different delivery method becomes mainstream clearpoint already had some big drugs in commercial. Not to mention clearpoint is on the frontlines so hopefully they continue to innovate and be where the puck is" [X Link](https://x.com/mike98572986/status/2020533955150381168) 2026-02-08T16:23Z [----] followers, [---] engagements "$clpt $rgnx ceo of regenxbio speaking on rgx [---] As I mentioned for the Hunter program we're in the middle of a BLA review now. So I won't speak to a lot of specifics about that but it's a very active review. Hunter I don't think there has been a new treatment in Hunter for [--] years. And so there's a huge unmet need here. We deliver directly to the CNS. And there's roughly [---] patients in the prevalent market per se for the U.S. And on an incident basis it's ultrarare so it's roughly [--] new patients per year. There's been a lot of advance in newborn screening for MPS and we want to come in" [X Link](https://x.com/mike98572986/status/2011596712314580999) 2026-01-15T00:30Z [----] followers, [----] engagements "$stpt $qure $clpt Good example on why fda needs to really value the doctors patients and parents real world evidence is a powerful thing. The doctors and parents were shouting from the rooftops that the drug works. Certain fda members were extremely skeptical and willing to pull the plug on ELEVIDYS they should eat a humble piece of pie today and realize they arent always correct. Dont own $Srpt but facts are facts that drug works exactly what parents and doctors were saying. At the end of the day you see enough things you have never seen before that isnt randomness at times you need to get" [X Link](https://x.com/mike98572986/status/2015809035845718220) 2026-01-26T15:28Z [----] followers, [----] engagements "$clpt $rgnx Paul Schmidt on LinkedIn Yesterday FDA froze two Regenxbio gene therapy programs after finding a brain tumor in one child. Here's what the press release doesn't sayand what rare disease families are thinking right now: : One 5-year-old. Treated [--] years ago. Asymptomatic tumor found on routine MRI. Causality undetermined. Meanwhile: [--] other patients on that same therapy. Clean. [--] patients on the sister therapy. Clean. Some dosed nearly [--] years ago. Both programs frozen. Including one that was [--] days from a potential FDA decision. : Hunter syndrome doesn't wait for" [X Link](https://x.com/mike98572986/status/2017093755065757989) 2026-01-30T04:33Z [----] followers, [----] engagements "The grand challenge he said is getting to the point where our AI models can design a variety of molecules with very specific properties almost like tailor-made medicine for a specific person and disease. Isomorphic is now a key player in an increasingly competitive race to revolutionise drug development with AI. Were developing these new technologies that have huge promise but in the end we need to make sure that these medicines are safe he said. Nothing will be gained by racing through and then putting something on the market that isnt going to help patients. He remains committed to finding" [X Link](https://x.com/mike98572986/status/2018017790691865021) 2026-02-01T17:45Z [----] followers, [---] engagements "$par very good write up" [X Link](https://x.com/mike98572986/status/2018494939299283121) 2026-02-03T01:21Z [----] followers, [----] engagements "$par added again I guess all software is going to zero -)" [X Link](https://x.com/mike98572986/status/2018757452624433350) 2026-02-03T18:44Z [----] followers, [----] engagements "$clpt Kaleida Health (KH) operates three main facilities in Erie County: Bualo General MedicalCenter/Gates Vascular Institute Millard Fillmore Suburban Hospital and John R. Oishei Childrens Hospital. To meet the needs of the community KH has established a weight management clinic at BGMC for adults and established an Eating Disorder Intensive Outpatient Program for children. Kaleida also oers youth suicide prevention services through connecting youth to mental health care. Additionally Kaleida operates a blood disorder clinic in collaboration with Roswell Park Comprehensive Cancer Center and" [X Link](https://x.com/mike98572986/status/2018760637888049625) 2026-02-03T18:56Z [----] followers, [---] engagements "$clpt Astellas abstract of pre-clinical work for the new stroke program asp2246 The median Cyno.mRS scores for the control low-dose and high-dose ASP2246 groups were [--] [--] and [--] respectively with significant improvement noted in the high-dose group compared to the saline control (p0.05). No ASP2246-related abnormalities were observed in clinical signs food consumption or body weight during the study period. Conclusions: ASP2246 a novel mRNA-LNP drug was able to convert astrocytes into neurons in a cell culture model and improved motor dysfunction in a chronic ischemic stroke cynomolgus monkey" [X Link](https://x.com/mike98572986/status/2018905712060166561) 2026-02-04T04:33Z [----] followers, [----] engagements "Minute 12:20 $qure $clpt here was the interview that we couldnt get to work from a couple weeks ago Can working up a sweat in a sauna improve your health Liam Gray and a patient that is part of the amt-130 trial and his experience. This study has shown it is possible to slow down the disease. It was a very very tightly matched population. It is a therapy that can be scaled up. Working on same day procedure in and out same day. The patient doesnt even like blood tests and was willing to do it. Jane Davis who was caring for the patient said once the results were released her workload increased" [X Link](https://x.com/mike98572986/status/2018940329731273205) 2026-02-04T06:50Z [----] followers, [----] engagements "$clpt Neurona cirm presentation Anyone that hasnt been following the Neurona program very closely should listen to the presentation from a couple days ago if you have followed my account with all the Neurona updates probably not worth it but if not its a good presentation" [X Link](https://x.com/mike98572986/status/2019065145809600695) 2026-02-04T15:06Z [----] followers, [----] engagements "$qure $clpt FDA document 2/2 Rare Disease Innovation Hub Goals Goal 1: Further Advance Regulatory Science of Rare Disease Therapies Create and enhance opportunities for consideration of novel endpoints biomarker development and assays innovative trial design real world evidence and statistical methods. Initiate engagement with federal research partners and the broader rare disease research community with the purpose of sharing scientific innovations and enhancing collaboration in regulatory science" [X Link](https://x.com/anyuser/status/2019068363121783227) 2026-02-04T15:19Z [----] followers, [----] engagements "$clpt Russell Lonser interview 17:53 talks about gene therapy and real time delivery about the [--] minute mark is where I would stop. Its a new paradigm We are now thinking about how do we scale this technology and techniques" [X Link](https://x.com/anyuser/status/2019151038494978096) 2026-02-04T20:48Z [----] followers, [----] engagements "Thursday Bluerocks program presentation 9:30 est if anyone is available would love to hear if anything interesting was said I will likely will not be able to attend either. $clpt Friday elad Levy [--] est might be the more interesting one. They do a lot with clearpoint" [X Link](https://x.com/mike98572986/status/2019289958385872998) 2026-02-05T06:00Z [----] followers, [---] engagements "$clpt Kenai If the brain can once again produce normal levels of dopamine Parkinsonsdiseasemaybe sloweddownandmotor functionrestoredsaidBrian LeeMDPhDaneurosurgeon with Keck Medicineandprincipalinvestigator of the study. We believe thattheseiPSCscanreliablymature into dopamine-producing braincellsandoffer the best chance of jump-starting the brainsdopamineproduction saidXenos Mason MD a neurologist who specializes inParkinsons disease and othermovement disorders with Keck Medicine and co-principal investigator of the study" [X Link](https://x.com/mike98572986/status/2019579991479243248) 2026-02-06T01:12Z [----] followers, [----] engagements "$clpt Irraflow TDC-FIT introduced in June [----] for recurrent or high-risk cSDH combined standard TDC with continuous pressure-controlled urokinase irrigation via a dual-lumen IRRAflow catheter or two single-lumen catheters connected to LiquoGuard [--]. This allowed regulated infusion and drainage to promote fibrinolysis while preventing pressure shifts. The introduction of TDC-FIT in [----] was accompanied by a rapid uptake with this technique representing 3.9% of cases in its first year and increasing to 12.6% in [----] TDC-FIT introduced in June [----] was performed in [--] cases (4.4%) mostly for" [X Link](https://x.com/mike98572986/status/2019990409649484153) 2026-02-07T04:23Z [----] followers, [---] engagements "$qure $clpt" [X Link](https://x.com/mike98572986/status/2020337749199659165) 2026-02-08T03:23Z [----] followers, [----] engagements "Very cool article" [X Link](https://x.com/mike98572986/status/2020528120214778194) 2026-02-08T16:00Z [----] followers, [---] engagements "$clpt this article is not about clearpoint but gives you an idea why clearpoint keeps winning a outsized amount of deals when it comes to trying to deliver to the brain. This industry doesnt mess around they like reliability and stuff that has worked. Its not worth the risk to try to get all fancy and just use some random start up for your delivery method. Joe said it best at the Mesa [----] when companies start looking for a company to use to deliver to the brain we are in a pretty unique position the fda knows our cannulas very well when getting your trial set up the fda takes about [--] months" [X Link](https://x.com/mike98572986/status/2020538023050625340) 2026-02-08T16:39Z [----] followers, [----] engagements "$qure $clpt @DesertDweller93" [X Link](https://x.com/mike98572986/status/2020599497014038778) 2026-02-08T20:43Z [----] followers, [----] engagements "RT @FierceBiotech: After facing a delay and clinical hold Regenxbios Hunter syndrome gene therapy has been rejected by the FDA. Fierce in" [X Link](https://x.com/mike98572986/status/2021065570117091704) 2026-02-10T03:35Z [----] followers, [--] engagements "$clpt Kenai At least [--] patients dosed so far" [X Link](https://x.com/mike98572986/status/2021739909518963157) 2026-02-12T00:15Z [----] followers, [---] engagements Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing
@mike98572986 mike
mike posts on X about $clpt, $qure, $4503t, health the most. They currently have [-----] followers and [--] posts still getting attention that total [-----] engagements in the last [--] hours.
Engagements: [-----] #
- [--] Week [-----] -22%
- [--] Month [------] -69%
- [--] Months [-------] +396%
- [--] Year [-------] +1,825%
Mentions: [--] #
- [--] Month [--] -70%
- [--] Months [---] +265%
- [--] Year [---] +2,219%
Followers: [-----] #
- [--] Week [-----] +0.31%
- [--] Month [-----] +3.90%
- [--] Months [-----] +145%
- [--] Year [-----] +433%
CreatorRank: [-------] #
Social Influence
Social category influence social networks 3.13% technology brands 3.13%
Social topic influence $clpt #3, $qure #23, $4503t #8, health 9.38%, $rgnx #17, real world #1358, ai 6.25%, in the 6.25%, $par #3, we are 6.25%
Top accounts mentioned or mentioned by @biggercapital @petermantas @desertdweller93 @profdollar @fiercebiotech @thephiloinvest @reignots @lvgtoft @long_only_guy @spacechocolate7
Top assets mentioned uniQure N.V. (QURE)
Top Social Posts
Top posts by engagements in the last [--] hours
"$clpt big time right here A Study of ASP2246 for People Who Have Movement Problems Caused by Brain Injury After a Stroke Astellas Pharma Inc Intracerebral parenchymal infusion via SmartFlow Neuro cannula. Procedure: Brain surgery Stereotactic brain surgery Study start 2026-02-09 [--] for enrollment @peter_mantas @biggercapital"
X Link 2026-01-08T02:51Z [----] followers, [----] engagements
"@biggercapital Yeah Astellas is no joke they likely saw clearpoints work on AviadoBio and were impressed with what they saw. This is definitely a big program and big partner to have"
X Link 2026-01-08T03:34Z [----] followers, [----] engagements
"$qure $clpt a good time to bring awareness to the disease Will Forte Gets Candid About His Family's Health Journey with Huntington's Disease"
X Link 2026-01-31T21:03Z [----] followers, [----] engagements
"I wouldnt go all in they are in a good position but a lot can go wrong. Just like a lot can also go right. My largest position but I believe so far the biggest risk is something coming out that is better and easier to deliver to the brain. There is definitely stuff out there working on this. I even actually expect it good news is that this industry moves extremely slow and by the time a different delivery method becomes mainstream clearpoint already had some big drugs in commercial. Not to mention clearpoint is on the frontlines so hopefully they continue to innovate and be where the puck is"
X Link 2026-02-08T16:23Z [----] followers, [---] engagements
"$clpt $rgnx ceo of regenxbio speaking on rgx [---] As I mentioned for the Hunter program we're in the middle of a BLA review now. So I won't speak to a lot of specifics about that but it's a very active review. Hunter I don't think there has been a new treatment in Hunter for [--] years. And so there's a huge unmet need here. We deliver directly to the CNS. And there's roughly [---] patients in the prevalent market per se for the U.S. And on an incident basis it's ultrarare so it's roughly [--] new patients per year. There's been a lot of advance in newborn screening for MPS and we want to come in"
X Link 2026-01-15T00:30Z [----] followers, [----] engagements
"$stpt $qure $clpt Good example on why fda needs to really value the doctors patients and parents real world evidence is a powerful thing. The doctors and parents were shouting from the rooftops that the drug works. Certain fda members were extremely skeptical and willing to pull the plug on ELEVIDYS they should eat a humble piece of pie today and realize they arent always correct. Dont own $Srpt but facts are facts that drug works exactly what parents and doctors were saying. At the end of the day you see enough things you have never seen before that isnt randomness at times you need to get"
X Link 2026-01-26T15:28Z [----] followers, [----] engagements
"$clpt $rgnx Paul Schmidt on LinkedIn Yesterday FDA froze two Regenxbio gene therapy programs after finding a brain tumor in one child. Here's what the press release doesn't sayand what rare disease families are thinking right now: : One 5-year-old. Treated [--] years ago. Asymptomatic tumor found on routine MRI. Causality undetermined. Meanwhile: [--] other patients on that same therapy. Clean. [--] patients on the sister therapy. Clean. Some dosed nearly [--] years ago. Both programs frozen. Including one that was [--] days from a potential FDA decision. : Hunter syndrome doesn't wait for"
X Link 2026-01-30T04:33Z [----] followers, [----] engagements
"The grand challenge he said is getting to the point where our AI models can design a variety of molecules with very specific properties almost like tailor-made medicine for a specific person and disease. Isomorphic is now a key player in an increasingly competitive race to revolutionise drug development with AI. Were developing these new technologies that have huge promise but in the end we need to make sure that these medicines are safe he said. Nothing will be gained by racing through and then putting something on the market that isnt going to help patients. He remains committed to finding"
X Link 2026-02-01T17:45Z [----] followers, [---] engagements
"$par very good write up"
X Link 2026-02-03T01:21Z [----] followers, [----] engagements
"$par added again I guess all software is going to zero -)"
X Link 2026-02-03T18:44Z [----] followers, [----] engagements
"$clpt Kaleida Health (KH) operates three main facilities in Erie County: Bualo General MedicalCenter/Gates Vascular Institute Millard Fillmore Suburban Hospital and John R. Oishei Childrens Hospital. To meet the needs of the community KH has established a weight management clinic at BGMC for adults and established an Eating Disorder Intensive Outpatient Program for children. Kaleida also oers youth suicide prevention services through connecting youth to mental health care. Additionally Kaleida operates a blood disorder clinic in collaboration with Roswell Park Comprehensive Cancer Center and"
X Link 2026-02-03T18:56Z [----] followers, [---] engagements
"$clpt Astellas abstract of pre-clinical work for the new stroke program asp2246 The median Cyno.mRS scores for the control low-dose and high-dose ASP2246 groups were [--] [--] and [--] respectively with significant improvement noted in the high-dose group compared to the saline control (p0.05). No ASP2246-related abnormalities were observed in clinical signs food consumption or body weight during the study period. Conclusions: ASP2246 a novel mRNA-LNP drug was able to convert astrocytes into neurons in a cell culture model and improved motor dysfunction in a chronic ischemic stroke cynomolgus monkey"
X Link 2026-02-04T04:33Z [----] followers, [----] engagements
"Minute 12:20 $qure $clpt here was the interview that we couldnt get to work from a couple weeks ago Can working up a sweat in a sauna improve your health Liam Gray and a patient that is part of the amt-130 trial and his experience. This study has shown it is possible to slow down the disease. It was a very very tightly matched population. It is a therapy that can be scaled up. Working on same day procedure in and out same day. The patient doesnt even like blood tests and was willing to do it. Jane Davis who was caring for the patient said once the results were released her workload increased"
X Link 2026-02-04T06:50Z [----] followers, [----] engagements
"$clpt Neurona cirm presentation Anyone that hasnt been following the Neurona program very closely should listen to the presentation from a couple days ago if you have followed my account with all the Neurona updates probably not worth it but if not its a good presentation"
X Link 2026-02-04T15:06Z [----] followers, [----] engagements
"$qure $clpt FDA document 2/2 Rare Disease Innovation Hub Goals Goal 1: Further Advance Regulatory Science of Rare Disease Therapies Create and enhance opportunities for consideration of novel endpoints biomarker development and assays innovative trial design real world evidence and statistical methods. Initiate engagement with federal research partners and the broader rare disease research community with the purpose of sharing scientific innovations and enhancing collaboration in regulatory science"
X Link 2026-02-04T15:19Z [----] followers, [----] engagements
"$clpt Russell Lonser interview 17:53 talks about gene therapy and real time delivery about the [--] minute mark is where I would stop. Its a new paradigm We are now thinking about how do we scale this technology and techniques"
X Link 2026-02-04T20:48Z [----] followers, [----] engagements
"Thursday Bluerocks program presentation 9:30 est if anyone is available would love to hear if anything interesting was said I will likely will not be able to attend either. $clpt Friday elad Levy [--] est might be the more interesting one. They do a lot with clearpoint"
X Link 2026-02-05T06:00Z [----] followers, [---] engagements
"$clpt Kenai If the brain can once again produce normal levels of dopamine Parkinsonsdiseasemaybe sloweddownandmotor functionrestoredsaidBrian LeeMDPhDaneurosurgeon with Keck Medicineandprincipalinvestigator of the study. We believe thattheseiPSCscanreliablymature into dopamine-producing braincellsandoffer the best chance of jump-starting the brainsdopamineproduction saidXenos Mason MD a neurologist who specializes inParkinsons disease and othermovement disorders with Keck Medicine and co-principal investigator of the study"
X Link 2026-02-06T01:12Z [----] followers, [----] engagements
"$clpt Irraflow TDC-FIT introduced in June [----] for recurrent or high-risk cSDH combined standard TDC with continuous pressure-controlled urokinase irrigation via a dual-lumen IRRAflow catheter or two single-lumen catheters connected to LiquoGuard [--]. This allowed regulated infusion and drainage to promote fibrinolysis while preventing pressure shifts. The introduction of TDC-FIT in [----] was accompanied by a rapid uptake with this technique representing 3.9% of cases in its first year and increasing to 12.6% in [----] TDC-FIT introduced in June [----] was performed in [--] cases (4.4%) mostly for"
X Link 2026-02-07T04:23Z [----] followers, [---] engagements
"$qure $clpt"
X Link 2026-02-08T03:23Z [----] followers, [----] engagements
"Very cool article"
X Link 2026-02-08T16:00Z [----] followers, [---] engagements
"$clpt this article is not about clearpoint but gives you an idea why clearpoint keeps winning a outsized amount of deals when it comes to trying to deliver to the brain. This industry doesnt mess around they like reliability and stuff that has worked. Its not worth the risk to try to get all fancy and just use some random start up for your delivery method. Joe said it best at the Mesa [----] when companies start looking for a company to use to deliver to the brain we are in a pretty unique position the fda knows our cannulas very well when getting your trial set up the fda takes about [--] months"
X Link 2026-02-08T16:39Z [----] followers, [----] engagements
"$qure $clpt @DesertDweller93"
X Link 2026-02-08T20:43Z [----] followers, [----] engagements
"RT @FierceBiotech: After facing a delay and clinical hold Regenxbios Hunter syndrome gene therapy has been rejected by the FDA. Fierce in"
X Link 2026-02-10T03:35Z [----] followers, [--] engagements
"$clpt Kenai At least [--] patients dosed so far"
X Link 2026-02-12T00:15Z [----] followers, [---] engagements
Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing